The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | CONPET: KRd consolidation in patients with multiple myeloma with a positive PET/CT after autoHSCT
Jakob Nordberg Nørgaard, PhD, Oslo University Hospital, Oslo, Norway, shares the results of CONPET (NCT03314636), a Phase II study evaluating the impact of carfilzomib-lenalidomide-dexamethasone (KRd) consolidation in patients with multiple myeloma with a positive [18F]-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) after first-line treatment with autologous hematopoietic stem cell transplantation (autoHSCT) and who have achieved a very good partial response (VGPR). Overall, the study found that 33% of patients were FDG PET/CT-positive after autoHSCT, and reported that 33% were converted from FDG PET/CT positivity to negativity after KRd consolidation. In addition, the study showed that MRD assessment and PET/CT were complementary techniques. The study is currently assessing progression-free survival (PFS) and overall survival (OS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
